Search Results - "Nauck, M. A."

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down by Nauck, M. A, Vardarli, I, Deacon, C. F, Holst, J. J, Meier, J. J

“…The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting…”
Get full text

comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study by Nauck, M. A, Duran, S, Kim, D, Johns, D, Northrup, J, Festa, A, Brodows, R, Trautmann, M

“…Aims/hypothesis The aim of this 52-week, open-label, non-inferiority trial was to compare the safety and efficacy of exenatide (an incretin mimetic) with that…”
Get full text

Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines-a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems by Bauer, S., Nauck, M. A.

“…Aims Our aim was to assess the number of medications prescribed to people with Type 1 or Type 2 diabetes mellitus and to compare these to recommendations by…”
Get full text

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans by Meier, J. J, Gethmann, A, Götze, O, Gallwitz, B, Holst, J. J, Schmidt, W. E, Nauck, M. A

“…Aims/hypothesis Diabetic dyslipidaemia contributes to the excess morbidity and mortality in patients with type 2 diabetes. Exogenous glucagon-like peptide 1…”
Get full text

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study by Nauck, M A, Ellis, G C, Fleck, P R, Wilson, C A, Mekki, Q

“…To evaluate the efficacy and safety of alogliptin, a new dipeptidyl peptidase-4 inhibitor, for 26 weeks at once-daily doses of 12.5 and 25 mg in combination…”
Get more information

Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? by Nauck, M. A., Baranov, O., Ritzel, R. A., Meier, J. J.

“…Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are incretin-derived glucose-lowering agents that have been used for the treatment of type 2 diabetes…”
Get full text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial by Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., Stein, P. P.

“…Aim:  To compare the efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and inadequate glycaemic control [haemoglobin A1c…”
Get full text

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes by Nauck, M A, Hompesch, M, Filipczak, R, Le, T D T, Zdravkovic, M, Gumprecht, J

“…Effects of the long acting GLP-1 analogue--liraglutide in subjects with type 2 diabetes. 144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were…”
Get more information

Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? by Meier, J J, Gallwitz, B, Schmidt, W E, Mügge, A, Nauck, M A

“…In the UGDP study, published in the 1970s, a high incidence of cardiovascular mortality was found in patients treated with the sulfonylurea agent tolbutamide…”
Get full text

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1 by Nauck, M A, El-Ouaghlidi, A

Get full text

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects by MEIER, J. J, DEACON, C. F, SCHMIDT, W. E, HOIST, J. J, NAUCK, M. A

“…The incretin effect describes the augmentation of postprandial insulin secretion by gut hormones. It is not known whether glucagon secretion is also influenced…”
Get full text

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects by Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., Holst, J. J.

“…Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in…”
Get full text

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes by METER, J. J, GALLWITZ, B, ASKENAS, M, VOLLMER, K, DEACON, C. F, HOIST, J. J, SCHMIDT, W. E, NAUCK, M. A

“…The insulinotropic effect of gastric inhibitory polypeptide (GIP) is reduced in patients with type 2 diabetes and around 50% of their first-degree relatives…”
Get full text

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients by NAUCK, M. A, KLEINE, N, ØRSKOV, C, HOLST, J. J, WILLS, B, CREUTZFELDT, W

“…Glucagon-like peptide 1 (GLP-1) (7-36 amide) is a physiological incretin hormone that is released after nutrient intake from the lower gut and stimulates…”
Get full text

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes by Nauck, M A

“…Glucagon-like peptide 1 (GLP-1) was discovered as an incretin (insulinotropic gut) hormone. Biological actions of GLP-1 in healthy and type 2 diabetic subjects…”
Get more information

enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms by Nauck, M. A, Meier, J. J

Get full text

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study by Weinstock, R S, Guerci, B, Umpierrez, G, Nauck, M A, Skrivanek, Z, Milicevic, Z

“…Aims To compare the once-weekly glucagon-like peptide-1 (GLP-1) receptor dulaglutide with the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin after…”
Get full text

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM by NAUCK, M. A, WOLLSCHLÄGER, D, WERNER, J, HOLST, J. J, ØRSKOV, C, CREUTZFELDT, W, WILLMS, B

“…Intravenous glucagon-like peptide (GLP)-1 [7-36 amide] can normalize plasma glucose in non-insulin-dependent diabetic (NIDDM) patients. Since this is no form…”
Get full text

Glucagon-like peptide 1 (GLP-1) by Müller, T.D., Finan, B., Bloom, S.R., D'Alessio, D., Drucker, D.J., Flatt, P.R., Fritsche, A., Gribble, F., Grill, H.J., Habener, J.F., Holst, J.J., Langhans, W., Meier, J.J., Nauck, M.A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D.A., Schwartz, T.W., Seeley, R.J., Stemmer, K., Tang-Christensen, M., Woods, S.C., DiMarchi, R.D., Tschöp, M.H.

“…The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the…”
Get full text

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations by Nauck, M A, Bartels, E, Orskov, C, Ebert, R, Creutzfeldt, W

“…Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1-(7-36) amide (GLP-1) are glucose-dependent insulinotropic gut hormones that may explain the…”
Get more information